StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
AQST's significant drop indicates investor concern over FDA's NDA issues, similar to past FDA rejections causing stock declines.
What happened, with direct paths to the underlying reporting
AQST stock dropped 40.18% after FDA's notification of NDA deficiencies. FDA did not specify deficiencies but ongoing review is crucial. Aquestive plans to respond to FDA before January 31, 2026 deadline. Company has $120 million cash for Anaphylm approval process. ARS Pharmaceuticals urged FDA to delay AQST’s epinephrine approval.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.